BEIJING, Sept. 12, 2025 /PRNewswire/ —  A report from China Daily

China’s intensified efforts to protect intellectual property rights (IPR) will help facilitate the cultivation of new quality productive forces and create immense business opportunities for multinational companies amid external challenges and uncertainties, experts and business leaders said at a high-level forum on Friday.

They said that IPR protection is playing an increasingly vital role in bolstering technological innovation, and injecting strong momentum into the country’s high-quality economic growth. They also called for the strengthening of global IP cooperation to further optimize the business environment for foreign companies operating in China.

The remarks were made during the “CEO: Grow with China” roundtable, which was organized by the Intellectual Property Publishing House Co Ltd and the China Daily Institute for Corporate Communication. It was a sideline event of the 14th China Intellectual Property Annual Conference, which opened in Beijing on Thursday.

Zhu Guangyao, China’s former vice-minister of finance, said, “In recent years, under the guidance of a new development concept, we have focused on innovation and made a close connection between intellectual property protection and innovation.”

Zhu described the enhancement of IPR protection as a “safeguard for innovation”.

Zhu said China is working to ensure that the strict regulations of its Patent Law and Copyright Law are being effectively enforced, adding that the country has also issued strict regulations on data and privacy protection, providing a strong foundation for the development of artificial intelligence.

Noting that China has intensified its focus on R&D intensity, and boasts abundant science and engineering university graduates, Liu Qiao, dean of Peking University’s Guanghua School of Management, said the country is quickly catching up with developed economies in terms of patent application intensity.

There is still room for improvement in the global competitiveness of Chinese IP, Liu added, emphasizing that more efforts should be made to increase investment in fundamental research, attract and develop top talents, and promote the industrial application of technological innovation.

According to the China National Intellectual Property Administration, the country has established partnerships with more than 80 countries and regions in the area of IP cooperation, while foreign applicants filed 94,000 trademark applications in China in the first half of 2025, representing a year-on-year increase of 7.4 percent.

Huge opportunities exist for multinational companies to invest in China and benefit from its expanding market, said Shirley Zhao, president of Astellas China, with staunch IPR protection included as part of the deal.

“We are investing in China, and we will continue to invest in China,” Zhao said.

“Better IPR protection and business environment boost our confidence, as well as the confidence of other multinational companies.”

Ian Shih, president of Rockwell Automation China, said China increasingly ensures equal treatment of domestic and foreign companies in IPR protection, particularly in terms of enforcement and policy implementation.

“The better business environment in China with respect to IP gives Rockwell greater confidence, security and enthusiasm to deepen our local engagement,” Shih said.

“Chinese IP laws and regulations are becoming not only world-class, but also very innovative,” said Rani Jarkas, chairman of Cedrus Group.

“That’s something very important, in my opinion, to protect companies and innovations. It actually encourages both foreign investments and domestic investments in innovation.”

David Blair, vice-president of the Beijing-based Center for China and Globalization, said, “In the US, we moved heavily toward monopolized economy.

“The amount of concentration in company domination in almost every sector is increasing dramatically. And somehow, that’s made possible through the use of the patent systems.

“So I’m encouraging China not to allow it to happen. It’s important to have IP, but it’s also important to ensure that IP doesn’t kill the competitive economy.”

BEIJING, Sept. 12, 2025 /PRNewswire/ — LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”), dated September 11, 2025, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) because the closing bid price for the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days. Furthermore, the Letter specifies that the Company is not eligible for the standard 180-day compliance period to regain compliance with the Bid Price Rule. The specific basis for this determination, as identified by Nasdaq, is Listing Rule 5810(c)(3)(A)(iv), which states that a company is ineligible for any compliance period if it has effected a reverse stock split within the prior one-year period. The Company effected a 10-for-1 reverse stock split on October 1, 2024.

Accordingly, the Letter indicates that Nasdaq has determined to delist the Company’s securities from The Nasdaq Capital Market. Unless the Company requests an appeal, trading in the Company’s securities will be suspended at the opening of business on September 22, 2025, and a Form 25-NSE will be filed with the Securities and Exchange Commission to remove the Company’s securities from listing and registration on The Nasdaq Stock Market.

The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by September 18, 2025. A request for a hearing would stay the suspension of the Company’s securities pending the Panel’s decision. The Company is currently evaluating the Nasdaq determination and considering its available options, including whether to request a hearing. There can be no assurance that the Company will appeal the determination, that any appeal would be successful, or that the Company will ultimately be able to regain compliance with the applicable Nasdaq listing requirements.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a delisting determination.

About LakeShore Biopharma

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA^® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit https://investors.lakeshorebio.com/.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the Board’s evaluation of the Proposal Letter and the Proposed Transaction. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “potential,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “goal,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma’s management and are not predictions of actual performance.

LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the Company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.

Streamlined Board to Support the Company’s Growth and Governance Objectives

BEIJING, Sept. 12, 2025 /PRNewswire/ — Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), a leading Chinese agricultural technology company, today announced the appointment of two new independent directors as part of a comprehensive board restructuring initiative. The Board of Directors (the “Board”) approved the appointments during a meeting held earlier today, implementing a streamlined governance structure that reduces the Board from seven to five members.

On September 11, 2025, Ms. Fei Wang, Dr. Michael Trimble, Dr. Min Lin, and Mr. Chi Kin Cheng, all directors of the Company, submitted letters of resignation indicating their intention to resign as the Company’s directors, effective September 12, 2025, which the Board has accepted. Mr. Cheng will remain as Chief Financial Officer of the Company.

The Company has appointed Dr. Changqing Mao as Independent Director and Chairman of the Nomination Committee, and Mr. Siu Laam Hau as Independent Director and Chairman of the Audit Committee. Both appointments are effective immediately and strengthen Origin’s corporate governance capabilities with seasoned expertise in agricultural industry leadership and financial oversight.

Dr. Changqing Mao brings exceptional agricultural industry expertise and senior executive leadership to Origin’s Board. Dr. Mao holds a Doctoral degree and currently serves as Co-Chairman of the Innovation and Entrepreneurship Research Center of China Agricultural University. His distinguished career includes serving as General Manager of CITIC AgriScience Co., Ltd., Chairman of Yuan Longping Agricultural High-Tech Co., Ltd., and Chairman of CITIC Agricultural Industry Fund Management Co., Ltd. Dr. Mao’s extensive background includes senior analytical and strategic roles at CITIC Securities, where he served as Chief Analyst of Agriculture, Forestry, Animal Husbandry and Fishery Industry and Chief Strategist. He holds a Bachelor’s degree in Economics from China Agricultural University, an MBA from Peking University’s Guanghua School of Management, and a Doctor of Law degree from Jilin University.

Mr. Siu Laam Hau contributes significant financial and corporate governance expertise to the Board. Mr. Hau is a Fellow Member of the Hong Kong Institute of Certified Public Accountants (HKICPA). He holds the Financial Risk Manager (FRM) designation from the Global Association of Risk Professionals. He currently serves as Executive Director of Asian Capital Limited, where he is licensed as a responsible officer to conduct corporate finance regulated activities. Mr. Hau previously served as Independent Non-Executive Director of Hong Kong-listed Trio Industrial Electronics Group Limited, where he chaired the remuneration committee and served on the audit and nomination committees. His professional experience spans corporate finance, restructuring services, and audit engagements with leading firms, including KPMG and PKF. Mr. Hau holds a Bachelor of Arts (Honours) degree with majors in Accountancy and Corporate Finance from The Hong Kong Polytechnic University.

“On behalf of the Board, I would like to thank our outgoing directors for their contributions and welcome Dr. Mao and Mr. Hau to Origin’s Board of Directors,” said Dr. Gengchen Han, Chairman of the Board of Origin Agritech. “Dr. Mao’s deep agricultural industry knowledge and proven track record in leading major agricultural enterprises will be invaluable as we continue to expand our biotechnology seed pipeline and market presence. Mr. Hau’s extensive financial expertise and corporate governance experience will strengthen our oversight capabilities and support our commitment to maintaining the highest standards of financial reporting and risk management.”

About Origin Agritech Limited

Origin Agritech Limited, founded in 1997 and headquartered in Origin R&D Center, Songzhuang, Tongzhou in Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company’s website at www.originagritech.com. The Company also maintains an X account for updating investors on Company and industry developments which is https://x.com/origin_agritech.

Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the federal securities laws, including Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements address expected future business and financial performance and financial condition and contain words like “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “will,” “would,” “target,” and similar expressions and variations. Forward-looking statements address matters that are uncertain. Forward-looking statements are not guarantees of future performance and are based on assumptions and expectations that may not be realized. They are based on management’s current expectations, assumptions, estimates, and projections about the Company and the industry in which the Company operates but involve a number of risks and uncertainties, many of which are beyond the Company’s control. Some of the important factors that could cause the Company’s actual results to differ materially from those discussed in forward-looking statements are: failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting our products; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; natural disasters and weather events and patterns; ability to protect and enforce the Company’s intellectual property rights; and separation of underperforming or non-strategic assets or businesses. The Company undertakes no duty or obligation to publicly revise or update any forward-looking statements as a result of future developments, new information, or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. Actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein. You are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

For more information, please contact:
Origin Agritech Limited Contact:
Kate Lang (Mandarin/English)
Director of Investor Relations
Phone: +86 186-1839-3368
Email: bing.lang@originseed.com.cn

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

GOTHENBURG, Sweden, Sept. 12, 2025 /PRNewswire/ — Minesto invites investors and the public with an interest in technology, energy systems and climate innovations to a unique opportunity to experience firsthand the tidal energy kite Dragon 4 ‘Íðunn’ as she is brought home for a break from production duty at the company’s demonstration site in the North Atlantic where it produces electricity to the Faroe Islands grid. The event will take place at Minesto workshop in Gothenburg, on 8 October 2025, 17.00-19.00.

Minesto, Swedish innovative scale-up company headquartered in Gothenburg, possesses a unique, proven, and commercially viable technology underway to contribute to the global energy transition by making 100% renewable energy systems affordable. With powerful, modular underwater power plants with an outstanding power-to-weight ratio, generating electricity from tidal streams and ocean currents, Minesto has positioned itself at the forefront of driving innovation in the global energy transition.

Now, for the first time, we open the doors to our workshop headquartered in Gothenburg to display one of our tidal power plants – a Dragon 4 (100 kW). ‘Íðunn’ as we call her, is brought home for a break from its production duty at demonstration site in the North Atlantic where it produces electricity to the Faroe Island grid.

We hereby proudly invite investors and the public to a unique opportunity to experience the Dragon 4, right here at our workshop in Göteborg on 8 October, 17.00-19.00.

Warm welcome.

Registration:

To join this event, please complete your registration here:

Minesto Dragon 4 Showcase

The event is free of charge and open to the public. Seats are limited, so we encourage early registration to secure your place.

Event summary

Date: 8 October 2025, Wednesday

Time: 17:00-19:00

Venue: Minesto Workshop, address J A Wettergrens gata 14, 421 30.

Please note the entrance to Minesto workshop where the event is taking place is at the back of the building (‘godsmottagningen’).

For parking, we kindly refer to the area parking lot Gruvgatan 6-8.

Program

Minesto showcases tidal energy kite ‘Dragon 4’

17.00 Doors open

17.15 Welcome and introduction to Minesto’s world-leading ocean energy technology and its value for the global energy transition, Dr Martin Edlund, CEO

17.30 The Dragon Class Technology, Bernt Erik Westre, CTO

17.45-19.00 Continued showcase of Íðunn and opportunity to meet Minesto technology experts

For media requests, please contact Cecilia Sernhage.

For additional information, please contact

Cecilia Sernhage, Chief Communications Officer
+46 735 23 71 58
ir@minesto.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/minesto-ab/r/invitation-to-showcase-of-tidal-energy-kite–dragon-4–at-minesto-workshop-in-gothenburg–8-october-,c4233673

The following files are available for download:

SHANGHAI, Sept. 12, 2025 /PRNewswire/ — Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN catheter and generator has received two Investigational Device Exemption (IDE) approvals—HDE study approved for patients with Group I PH patients, PMA study approved for patients with Group II PH patients, with CMS full coverage approval, paving the way for upcoming clinical trials in the United States.

Following the FDA’s BDD designation granted in 2021 for Groups I, II, and IV, the newly obtained IDE approvals will advance clinical studies targeting Groups I and II into the IDE stage. These trials focus on different patient groups—Group I (Pulmonary Arterial Hypertension, PAH) and Group II (PH due to left heart disease)—with the aim of validating the efficacy and safety of PADN technology in the treatment of these conditions. Both clinical trials are important for evaluating the use of PADN in diverse populations with pulmonary hypertension and heart failure. This IDE approval, coupled with the full coverage by CMS in the U.S., has significantly advanced the clinical application and market acceptance of the PADN system, providing critical data to support Pulnovo Medical’s further commercialization efforts in the U.S.

PADN has received FDA HUD designation, is approved by the NMPA, and is CE-marked, meaning it meets high safety and efficacy standards globally. Pulmonary Artery Denervation (PADN) offers more options for both Group I pulmonary arterial hypertension patients with limited response to existing drug therapies and Group II pulmonary hypertension patients, who currently have no specifically approved treatment. With over 1,000 clinical applications across countries such as Portugal, Georgia, Singapore, Malaysia, and China, PADN products have consistently demonstrated a strong safety profile and therapeutic efficacy in real-world settings.

The IDE approval marks a critical step in Pulnovo Medical’s commitment to delivering innovative, high-quality solutions for patients with pulmonary hypertension and accelerating the global expansion of PADN technology. The results of these studies will generate valuable data to further validate the potential of PADN. Progress in these clinical trials is expected to bring meaningful benefits to patients, including improved exercise tolerance in daily life and a better overall quality of life.